health care cost

Research Reports

Clinical Pathways: A Current Snapshot, and the Journey Ahead

03/15/2017

Amy Schroeder, RPh

03/15/2017

Journal of Clinical Pathways

Research in Review

12/29/2016

JCP Editors

A new study sheds light on factors that make it more likely patients with cancer will not adhere to their treatment because of cost reasons. ----- Related Content Cognitive Factors Linked to Treatment Adherence in...

A new...

12/29/2016

Journal of Clinical Pathways

Research in Review

NCCN Responds to Study Findings on Financial Conflicts of Interest

11/04/2016

JCP Editors

The National Comprehensive Cancer Network (NCCN) agreed that ongoing monitoring and research regarding financial conflicts of interest (COIs) at the interface of academia, medicine, and industry is critical,...

The...

11/04/2016

Journal of Clinical Pathways

Research in Review

Addition of Panobinostat to Multiple Myeloma Care Has Little Economic Impact

09/06/2016

JCP Editors

Adding panobinostat to treatment regimens for multiple myeloma would have a minimal economic impact and could even save the health care system money, claims a study published in the Journal of Managed Care &...

Adding...

09/06/2016

Journal of Clinical Pathways

Research in Review

Process for Reimbursing Off-Label Cancer Drug Use Questioned

09/01/2016

JCP Editors

Off-label drug use, which is widely practiced in oncology care, accounted for $5 billion in cancer drug costs in 2010. Now a team of researchers is recommending an overhaul of the process that determines which cancer...

...

09/01/2016

Journal of Clinical Pathways

Pharma Insights

Companion Diagnostics and Complementary Diagnostics in Clinical Practice: Better Medicine or Competitive Disadvantage?

05/06/2016

David Parker, PhD

Larry Blandford, PharmD—Column Editor

We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in...

We are...

05/06/2016

Journal of Clinical Pathways

Pharma Insights

When Medication Price Deflates Perception of Therapeutic Effect

04/11/2016

Larry Blandford, PharmD—Column Editor

Stephen C Carter

Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...

...

04/11/2016

Journal of Clinical Pathways

Research in Review

Drug Combinations Cost-Effective for Reducing Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma

03/08/2016

JCP Editors

A study comparing seven prophylaxis strategies for reducing the risk of febrile neutropenia (FN) in patients with non-Hodgkin lymphoma receiving chemotherapy found that routine primary prophylaxis (PP) with...

...

03/08/2016

Journal of Clinical Pathways

Research in Review

Multiple-Treatment Regimens for Colorectal Cancer Have High Costs and Little Benefit to Elderly Patients

03/02/2016

JCP Editors

A 10-year study has found that the rate of elderly patients receiving 3 or more treatments for metastatic colorectal cancer has increased substantially from 2000 to 2009, but that added agents may not lead to...

A...

03/02/2016

Journal of Clinical Pathways

Research in Review

Costs for High-Risk Patients With ALL Increasing

02/25/2016

JCP Editors

Costs for high-risk pediatric and adolescent patients with acute lymphoblastic leukemia (ALL) may be higher than standard-risk patients with the disease, according to a recent study. While data regarding health care...

Costs...

02/25/2016

Journal of Clinical Pathways